2024
Current management practices of de novo oligometastatic breast cancer: Real-world data from a physician survey.
Odzer N, Pusztai L, Rozenblit M. Current management practices of de novo oligometastatic breast cancer: Real-world data from a physician survey. Journal Of Clinical Oncology 2024, 42: 1104-1104. DOI: 10.1200/jco.2024.42.16_suppl.1104.Peer-Reviewed Original ResearchMultimodal therapySurgical resectionOverall survivalPrimary tumorRandomized trialsResponse to initial chemotherapyTreated with multimodality therapyOligometastatic breast cancerRecommended surgical resectionLocally advanced cancerPalliative systemic chemotherapyProlonged overall survivalTime of diagnosisRandomized clinical trialsOS benefitSystemic chemotherapyInitial chemotherapyResidual lesionsSurvival benefitNCCN GuidelinesReceptor subtypesRetrospective studyTreatment modalitiesMetastatic cancerAblative radiation
2017
Impacts of Early Guideline-Directed 21-Gene Recurrence Score Testing on Adjuvant Therapy Decision Making
Dzimitrowicz H, Mougalian S, Storms S, Hurd S, Chagpar AB, Killelea BK, Horowitz NR, Lannin DR, Harigopal M, Hofstatter E, DiGiovanna MP, Adelson KB, Silber A, Abu-Khalaf M, Chung G, Zaheer W, Abdelghany O, Hatzis C, Pusztai L, Sanft TB. Impacts of Early Guideline-Directed 21-Gene Recurrence Score Testing on Adjuvant Therapy Decision Making. JCO Oncology Practice 2017, 13: jop.2017.022731. PMID: 29048991, DOI: 10.1200/jop.2017.022731.Peer-Reviewed Original ResearchConceptsAdjuvant therapy decisionsRecurrence scoreChemotherapy useRS testingMedical oncologistsHistorical controlsChemotherapy decisionsTherapy decisionsEligibility criteriaNational Comprehensive Cancer Network guidelinesProspective quality improvement projectEarly-stage breast cancerAdjuvant chemotherapy recommendationsTime of diagnosisTime of surgeryQuality improvement projectTesting groupChemotherapy initiationChemotherapy recommendationsMedian timeTrial enrollmentNetwork guidelinesSurgical oncologistsClinical trialsBreast cancer
2012
Evaluation of circulating biomarkers of bone metastases in early-stage breast cancer.
Dean-Colomb W, Hess K, Young E, Gornet T, Handy B, Moulder S, Ibrahim N, Pusztai L, Booser D, Valero V, Hortobagyi G, Esteva F. Evaluation of circulating biomarkers of bone metastases in early-stage breast cancer. Journal Of Clinical Oncology 2012, 30: 10-10. DOI: 10.1200/jco.2012.30.30_suppl.10.Peer-Reviewed Original ResearchP1NP levelsBreast cancerStage IInterleukin-6Cox proportional hazards regression analysisStage IV breast cancerElecsys 2010Proportional hazards regression analysisKaplan-Meier methodTime of diagnosisHazards regression analysisWorse overall survivalBone metastasis developmentProcollagen type 1Breast cancer recurrenceRoche Elecsys 2010Advanced diseaseMetastatic diseaseOverall survivalBone metastasesClinical factorsSerum levelsSerum P1NPBone turnoverBiomarker levels
2011
P2-12-06: Nomogram To Predict Subsequent Bone Metastasis in Patients with Non Metastatic Breast Carcinomas.
Lousquy R, Delpech Y, Rouzier R, Gligorov J, Hsu L, Barranger E, Pusztai L, Uzan S, Hortobagyi G, Coutant C, Ibrahim N. P2-12-06: Nomogram To Predict Subsequent Bone Metastasis in Patients with Non Metastatic Breast Carcinomas. Cancer Research 2011, 71: p2-12-06-p2-12-06. DOI: 10.1158/0008-5472.sabcs11-p2-12-06.Peer-Reviewed Original ResearchNon-metastatic breast cancerMetastatic breast cancerBreast cancerBone metastasesConcordance indexHigh riskCox proportional hazards regression modelNon-metastatic breast carcinomaMultivariate logistic regression analysisProportional hazards regression modelsM.D. Anderson Cancer CenterBreast cancer molecular subtypesMethods Medical recordsSubsequent bone metastasesLymph node statusLymphovascular space invasionSelection of patientsTime of diagnosisMetastatic breast carcinomaHazards regression modelsAnderson Cancer CenterCancer molecular subtypesLogistic regression analysisDesign of trialsAdjuvant hormonotherapy